trimodality

Resection margins, extrapleural nodal status, and cell type determine survival in trimodality therapy of malignant pleural mesothelioma (MPM): Results in 183 patients.

Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database.

Although surgery, by itself, is not very effective, surgery combined with adjuvant chemotherapy and radiation (trimodality therapy) has produced significant survival extension (3-14 years) among patients with favorable prognostic factors.